title: Phase 1 clinical study of cyclophilin B peptide vaccine for patients with lung cancer.
abstract: Cyclophilin B (CypB) possesses two antigenic epitopes (CypB(84-92) and CypB(91-99) ) recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes (CTLs). To determine the safety of CypB-derived peptides and its ability to generate antitumor immune responses, patients with advanced lung cancer received subcutaneous vaccinations of these peptides or their modified peptides. All 16 patients were vaccinated with CypB(91-99) or its modified peptide, whereas only two patients were vaccinated with the modified CypB(84-92), as immediate-type hypersensitivity to CypB(84-92) or its modified peptide was observed in the remaining patients. No severe adverse events were associated with the vaccination. No significant increase in cellular responses to either peptides or tumor cells was observed in the postvaccination PBMCs by the conventional CTL assays in any patients tested. These results suggest that the vaccination of CypB(91-99) peptide was safe, but failed to induce objective immune responses at this regimen.
authors.affiliation: Department of Internal Medicine, Kurume University School of Medicine, Japan.
authors.forename: Rumi
authors.initials: R
authors.lastname: Gohara
authors.forename: Nobue
authors.initials: N
authors.lastname: Imai
authors.forename: Toru
authors.initials: T
authors.lastname: Rikimaru
authors.forename: Akira
authors.initials: A
authors.lastname: Yamada
authors.forename: Naoya
authors.initials: N
authors.lastname: Hida
authors.forename: Masao
authors.initials: M
authors.lastname: Ichiki
authors.forename: Mayumi
authors.initials: M
authors.lastname: Kawamoto
authors.forename: Kazuko
authors.initials: K
authors.lastname: Matsunaga
authors.forename: Junko
authors.initials: J
authors.lastname: Ashihara
authors.forename: Sayoko
authors.initials: S
authors.lastname: Yano
authors.forename: Mayumi
authors.initials: M
authors.lastname: Tamura
authors.forename: Shinya
authors.initials: S
authors.lastname: Ohkouchi
authors.forename: Hideaki
authors.initials: H
authors.lastname: Yamana
authors.forename: Kotaro
authors.initials: K
authors.lastname: Oizumi
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
mesh_terms: D000328:Adult; D000368:Aged; D019496:Cancer Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D021983:Cyclophilins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019696:Peptidylprolyl Isomerase; D012449:Safety; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D019496:Cancer Vaccines; D014614:Vaccines, Synthetic; C081786:cyclophilin B; D021983:Cyclophilins; D019696:Peptidylprolyl Isomerase